Search publications
Title: Monitoring HPV vaccination programmes
Authors: Canfell K
Categories: Cancer Type - Cervical Cancer
Cancer Control, Survivorship, and Outcomes Research - Health Services, Economic and Health Policy Analyses
Keywords: Abortion,Spontaneous; Humans; Netherlands; Papillomavirus Infections; Papillomavirus Vaccines; pregnancy; prevention & control; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms; Vaccination; adverse effects; cancer; Cancer Vaccines; Cervical Intraepithelial Neoplasia; chemically induced; Female; Great Britain; HPV
Year: 2010
Journal Title: BMJ
Volume: 340
Page number start: c1666
Abstract: Trials of bivalent vaccine show no association with pregnancy loss, but ongoing surveillance is recommended Vaccines based on human papillomavirus (HPV) types 16 and 18 virus-like particles (VLPs) are highly effective in preventing the development of HPV 16/18 related high grade cervical intraepithelial neoplasia (CIN2+) in HPV naive females. Gardasil (Merck) is a quadrivalent HPV 16/18/6/11 vaccine formulated with a proprietary aluminium adjuvant; and Cervarix (GlaxoSmithKline) is a bivalent HPV 16/18 vaccine incorporating a novel adjuvant, AS04. In the linked study (doi:10.1136/bmj.c712), Wacholder and colleagues report a pooled analysis of data on pregnancy loss from two randomised controlled trials of Cervarix vaccine.1 The bivalent vaccine was licensed in the European Union in 20072 and approved by the Food and Drug Administration in the United States in October 2009,3 and has been selected for use in the national public HPV vaccination programmes of the Netherlands and the United Kingdom. In the UK, vaccination started in September 2008, and at least 3.5 million doses have been administered.4 In England, three dose coverage in 12-13 year old girls is estimated at 80%; catch-up to age 18 will be conducted over approximately two years, with recent three dose coverage reported as 32% in 17-18 year old females.5 Prophylactic VLP HPV vaccines do not contain live virus. A broad consensus exists among regulatory authorities that, although no evidence suggests that HPV vaccines confer additional risk during pregnancy, the safety of vaccinating pregnant women has not been established.2 3 4 Thus, neither of the HPV vaccines are recommended for use in pregnancy or in women planning to become …
Programme: Epi Mod Screen
Division: Cancer Research Division
DOI: https://doi.org/10.1136/bmj.c1666
URI: http://researchpubs.cancercouncil.com.au/cancercounciljspui/handle/1/1506
Appears in Collections:Research Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.